Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address ...
GlobalData on MSN
Teva and Sanofi’s TL1A mAb shows durability in UC and CD
In the Phase IIb trial, the drug was still benefiting patients after 58 weeks of treatment.
Teva Pharmaceutical (TEVA) and Medincell (MDCLF) announce FDA review for long-acting olanzapine developed with Royalty Pharma ...
Corcept Therapeutics Inc CORT shares are under heavy pressure Thursday morning after the U.S. Court of Appeals for the ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is given the second ...
Teva Pharmaceutical Indus (NYSE: TEVA) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of ...
Sanofi and Teva had already shown in late 2024 that the anti-TL1A antibody, called duvakitug, improved outcomes in ulcerative ...
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well ...
Corcept Therapeutics lost its patent-infringement battle with Teva Pharmaceutical Industries, exposing Corcept to more competition from generic drugs. The ruling from the U.S. Court of Appeals for the ...
Corcept Therapeutics (CORT) stock plunged after an appeals court backed Teva (TEVA) in a patent dispute over the company's lead drug Korlym. Read more here.
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results